| CAS NO: | 2152-44-5 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Molecular Weight (MW) | 476.58 |
|---|---|
| Formula | C27H37FO6 |
| CAS No. | 2152-44-5 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 95 mg/mL (199.3 mM) |
| Water: <1 mg/mL | |
| Ethanol: 58 mg/mL (121.7 mM) | |
| Other info | Chemical Name: (8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl pentanoate InChi Key: SNHRLVCMMWUAJD-SUYDQAKGSA-N InChi Code: InChI=1S/C27H37FO6/c1-5-6-7-23(33)34-27(22(32)15-29)16(2)12-20-19-9-8-17-13-18(30)10-11-24(17,3)26(19,28)21(31)14-25(20,27)4/h10-11,13,16,19-21,29,31H,5-9,12,14-15H2,1-4H3/t16-,19-,20-,21-,24-,25-,26-,27-/m0/s1 SMILES Code: O=C1C=C[C@@]2([C@]3([C@H](C[C@@]4([C@](OC(CCCC)=O)([C@H](C[C@]4([C@@]3(CCC2=C1)[H])[H])C)C(CO)=O)C)O)F)C |
| Synonyms | BV; BET; Betoid; Valison; 9α-Fluo; Valisone; Bedermin; Betneval; Beta-Val; Bextasol; Dermosol; Stanoval; betamethasone 17-valerate; Betamethasone Valerate |
| In Vitro | In vitro activity: The presence of BV at a concentration of 4.6 mM/l provoked a still further diminuition of the G-6-PDH-activity of human skin homogenates that followed the incubation for 120 min at 37°C in media containing 5% dimethylformamide and in which the concentration of G-6-PDH changed from about 55 mU/ml to 9 mU/ml. |
|---|---|
| In Vivo | Compared with sodium cromoglycate (SCG, 80mg daily), treatment of betamethasone valerate (BV, 800μg daily) for 4 weeks made children requiring bronchodilators for perennial asthma significantly require less bronchodilator drugs, and have fewer symptoms and higher daily peak expiratory flow rates. Compared with coal tar (10% LCD) cream, after a 2 week wash-out period, treatment with betamethasone valerate cream (0.1%) twice daily for 6 weeks made patients with stable, mild-moderate plaque psoriasis get more mean reduction of PASI score from baseline. The final effect of betamethasone valerate was significantly greater clearance and improvement . |
| Animal model | |
| Formulation & Dosage | |
| References | Spectrochim Acta A Mol Biomol Spectrosc. 2015 Apr 5;140:294-304; Br Med J. 1971 Jul 10;3(5766):84-6; J Pharm Biomed Anal. 2011 Jan 5;54(1):242-7. |
m.cnreagent.com